Your browser doesn't support javascript.
loading
Evidence for choosing biologic disease-modifying anti-rheumatic drugs in the treatment of Behçet disease.
Kubo, Hiroshi; Ouchi, Kazutaka; Nakagawa, Norio; Akioka, Shinji.
Affiliation
  • Kubo H; Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan. Electronic address: k-hiro@koto.kpu-m.ac.jp.
  • Ouchi K; Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan.
  • Nakagawa N; Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan.
  • Akioka S; Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan.
Semin Arthritis Rheum ; 47(1): e1, 2017 08.
Article in En | MEDLINE | ID: mdl-28413101
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Behcet Syndrome / Antirheumatic Agents Limits: Humans Language: En Journal: Semin Arthritis Rheum Year: 2017 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Behcet Syndrome / Antirheumatic Agents Limits: Humans Language: En Journal: Semin Arthritis Rheum Year: 2017 Document type: Article